Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.46 |
| ▸ | PTGER1 | P34995 | 6/20 | 0.44 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | MITF | O75030 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | XBP1 | P17861 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | KMO | O15229 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7910724 | 0.82 | MAOA (0.47) | MEN1KMT2A | |
| SCHEMBL1578341 | 0.81 | BRD4 (0.48) | MRGPRX4PTGER1HPGDNPC1SMN1; SMN2 | |
| SCHEMBL20427872 | 0.77 | BRD4 (0.49) | MRGPRX4PTGER1HPGDNPC1SMN1; SMN2 | |
| SCHEMBL14124832 | 0.77 | MAP4K4 (0.42) | MEN1KMT2A | |
| SCHEMBL2949761 | 0.76 | KDM4E (0.40) | MRGPRX4PTGER1HPGDNPC1SMN1; SMN2 | |
| SCHEMBL20427873 | 0.76 | CYP2C9 (0.41) | MRGPRX4PTGER1HPGDNPC1SMN1; SMN2 | |
| SCHEMBL1751462 | 0.75 | CYP1A2 (0.70) | HPGDNPC1SMN1; SMN2MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL6818272 | 0.74 | CYP1A2 (0.68) | HPGDNPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL383618 | 0.74 | FOLH1 (0.58) | MRGPRX4PTGER1HPGDNPC1SMN1; SMN2 | |
| SCHEMBL3103763 | 0.74 | L3MBTL1 (0.44) | MRGPRX4PTGER1HPGDNPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2310377-B1 | 5-PHENYL-ISOXAZOLE-3-CARBOXAMIDES MODULATING HSP90 WITH ANTITUMORAL ACTIVITIES | SIGMA TAU RES SWITZERLAND SA (CH) | 2015-09-16 | — | — | EP | disclosed |
| US-8383616-B2 | Aryl isoxazole compounds with antitumoural activities | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE SPA (IT) | 2013-02-26 | — | — | US | disclosed |
| US-20110245221-A1 | ARYL ISOXAZOLE COMPOUNDS WITH ANTITUMOURAL ACTIVITIES | SIGMA-TAU RESEARCH SWITZERLAND S.A. (CH) | 2011-10-06 | — | — | US | disclosed |
| EP-2310377-A1 | 5-PHENYL-ISOXAZOLE-3-CARBOXAMIDES MODULATING HSP90 WITH ANTITUMORAL ACTIVITIES | SIGMA-TAU Research Switzerland S.A. (CH) | 2011-04-20 | — | — | EP | disclosed |
| WO-2010000748-A1 | 5-PHENYL-ISOXAZOLE-3-CARBOXAMIDES MODULATING HSP90 WITH ANTITUMORAL ACTIVITIES | SIGMA-TAU RESEARCH SWITZERLAND S.A. (CH) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245221-A1 | ARYL ISOXAZOLE COMPOUNDS WITH ANTITUMOURAL ACTIVITIES | HSP90AB1, HSP90AB2P, HSP90AA1 | MRGPRX4 792/4885PTGER1 3559/4885HPGD 629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.